Prof Manal Abdelmalek, USA highlights the role that PPAR agonists could play in the treatment of NASH. This video was filmed in Boston during the Liver meeting 2019.

Prof Gyongyi Szabo, USA discusses the role of PPARs in NASH fibrogenesis. This video was filmed in Boston during the Liver meeting 2019.

Prof Frank Tacke, Germany, discusses the role of PPARs in adipose tissue and liver inflammation. This video was filmed in Boston during the Liver meeting 2019.

Prof Sven Francque, Belgium discusses the value of the clinical trials results presented in Boston during the Liver meeting 2019.

The conference will take place in London, UK on April 15-19, 2020. At ILC 2020, doctors, patients, allied health professionals and policymakers will discuss the important new insights and information to help them combat liver disease, including specific sessions dealing with NASH.

Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.

A recent article by Zaki A. Sherif states that there is a proven lack of a full understanding about NAFLD and NASH. It can adversely impact patients, health professionals, health providers, and researchers alike. The biggest challenge is to increase awareness and improve education.

The aim of this very interesting study by L. Serfaty et al. was to assess the prevalence and riskfactors of NAFLD and associated liver fibrosis in a French population-based cohort (118, 664participants) by using using the Fatty Liver Index and Forns Index.

Almost 10,000 hepatologists and hepatology heath care professionals, researchers and clinicians, gathered in Boston to exchange the latest liver disease information. NASH and NAFLD were an integral component of this international scientific forum.